Calidi Biotherapeutics is facing delisting of warrants due to low trading price

From GlobeNewswire: 2024-10-18 23:00:00

Calidi Biotherapeutics, Inc. is facing delisting of its warrants (CLDI WS) from the NYSE American due to low trading price. The company’s common stock (CLDI) will continue trading, while the warrants will be suspended immediately. Calidi has the right to appeal this decision in front of the Listings Qualifications Panel. The biotechnology company focuses on developing targeted antitumor virotherapies utilizing stem cells and oncolytic viruses. Calidi’s technology aims to enhance efficacy and improve patient safety in treating various oncology indications, including high-grade gliomas and solid tumors. For more information, visit www.calidibio.com.



Read more at GlobeNewswire: NYSE American to Commence Delisting Proceedings with